TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| A Guilt-Free Hamburger New research shows that some types of unprocessed red meat don't increase the risk of heart disease. But salt-heavy processed meats, such as bacon and sausage, do up the risk. online.wsj.com |
Vivus's Qnexa Gets Thumbs Down From Mixed FDA Panel Ruthanne Williams Roussel submits:As many will know by now, an FDA briefing panel July 15 recommended against approval of Vivus' (VVUS) obesity drug candidate Qnexa by a vote of 10 to 6. This was originally announced as a vote of 9 to 7, but a new electronic voting system was in use, and it must have been a little confusing, because one panelist later claimed that they had unintentionally voted "Yes" for approval instead of "No" against. (Insert "Jim, I'm a doctor, not an electronic voter!" joke here.) The main concerns cited about Qnexa were:Complete Story » seekingalpha.com |
Clarient to Present at Two Investor Conferences in August (PR Newswire) Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today announced that the Company is scheduled to make investor presentations at two investor conferences in the month of August. us.rd.yahoo.com |
Endo Pharmaceuticals Acquires Apax's Qualitest for $1.2B U.S.-based specialty healthcare company Endo Pharmaceuticals (NASDAQ:ENDP) has agreed to buy Qualitest Pharmaceuticals, the sixth largest generic pharmaceutical company in the U.S., for around $1.2 billion in cash from London-based buyout shop Apax Partners, it said Tuesday. Huntsville, Alabama-based Qualitest manufactures controlled substances from its facilities in the U.S., which make up approximately 40% of its product portfolio, with liquids making up the remaining 17% of its portfolio. Thirty-two of Qualitest's products are listed among the top 250 generics by total prescription (TRx) volume.Complete Story » seekingalpha.com |
Abbott Profit Falls 40% on Acquisition, Recall Costs Abbott reported a 40% drop in third-quarter earnings, weighed down by costs associated with layoffs, a baby-formula recall and the withdrawal of a diet drug due to safety concerns. online.wsj.com |